Baytril 2.5% Oral Solution

Introduction

Company name: Bayer plc
Address: Animal Health Division
Bayer House, Strawberry Hill, Newbury
Berkshire RG14 1JA
Telephone: 01635 563000
Fax: 01635 563622
Email: animal.health@bayerhealthcare.com
Website: www.bayer.co.uk/products/animalhealth.html

Presentation

A ready to use clear aqueous oral solution containing as active ingredient 25 mg/ml enrofloxacin, and 14 mg/ml benzyl alcohol (Ph.Eur.) as a preservative.

Uses

Enrofloxacin is a synthetic, broad spectrum antimicrobial substance, belonging to the fluoroquinolone group of antibiotics. It is bactericidal in action with activity against many gram positive and gram negative bacteria as well as mycoplasmas.

Baytril 2.5% Oral Solution is indicated for use in calves for the treatment of infections of the respiratory and alimentary tract of bacterial or mycoplasmal origin (e.g. pasteurellosis, mycoplasmosis, coli-bacillosis and salmonellosis), where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

Baytril 2.5% Oral Solution may also be used in exotic animals (small mammals, reptiles and avian species) for the treatment of bacterial infections of the alimentary and respiratory tracts where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

Dosage and administration

Calves

Baytril 2.5% Oral Solution is administered via the milk, milk replacer, electrolyte solution or water. The dose rate is 2.5 mg per kg body weight (5 ml per 50 kg) daily for 3 days. This rate may be doubled to 5 mg per kg (10 ml per 50 kg) for 5 days for salmonellosis and complicated respiratory disease. Medicated fluids should be made up immediately prior to provision on a daily basis.

Exotic animals

See Table 1.

The dose rates given are for guidance only. Veterinary surgeons are advised to contact the company prior to use to discuss the particulars of each individual case.

Table 1: Dosage for Baytril 2.5% Oral Solution

<table>
<thead>
<tr>
<th>Species</th>
<th>Dosage</th>
<th>Route</th>
<th>Dose Frequency</th>
<th>Treatment period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small mammals</td>
<td>5 mg enrofloxacin per kg bodyweight (0.2 ml/kg bw)</td>
<td>Orally diluted in water</td>
<td>Twice daily</td>
<td>7 days</td>
</tr>
<tr>
<td>Reptiles</td>
<td>5 mg enrofloxacin per kg bodyweight (0.2 ml/kg bw)</td>
<td>Orally diluted in water</td>
<td>24-48 hour intervals</td>
<td>6 days</td>
</tr>
<tr>
<td>Birds (excluding chickens and turkeys)</td>
<td>10 mg enrofloxacin per kg bodyweight (0.4 ml/kg bw)</td>
<td>Orally diluted in water</td>
<td>Twice daily</td>
<td>7 days</td>
</tr>
</tbody>
</table>

For direct administration by gavage, dilutions of 1 part Baytril 2.5% Oral Solution to 4 parts water are recommended. If the product is to be given via the drinking water, concentrations of between 50 and 200 ppm should be considered as suitable working dilutions. Concentrations in excess of 250 ppm should be avoided as precipitation may occur. The dilution should be made on a daily basis, immediately prior to provision, preferably in a glass container. The use of 0.5 ml (100 unit) insulin syringe should be considered for the withdrawal of the very small volumes of Baytril 2.5% Oral Solution required for dilution prior to administration.

Treatment may be initiated with Baytril 2.5% Injection and maintained with Baytril 2.5% Oral Solution. Medicated fluids should be made up immediately prior to provision on a daily basis.

Use during pregnancy and lactation

In the absence of data on its use in some exotic species, caution should be used when prescribing during these periods and a careful risk/benefit assessment made.
Contraindications, warnings, etc
Baytril 2.5% Oral Solution should not be used for prophylaxis.
Consult the Technical Services Department of Bayer prior to use in exotic animals.
Official and local antimicrobial policies should be taken into account when the product is used.
Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly,
or are expected to respond poorly, to other classes of antimicrobials.
Wherever possible, fluoroquinolones should only be used on susceptibility testing.
Use of the product deviating from the instructions given on the SPC may increase the prevalence of
bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other
quinolones due to the potential for cross resistance.
During the period of rapid growth, enrofloxacin may affect articular cartilage. In the absence of data on its
use in some exotic species, caution should be used when prescribing during these periods and a careful
risk/benefit assessment made.
Do not exceed the recommended dose. In accidental overdose there is no antidote and treatment should
be symptomatic.
For animal treatment only.
This product should not be used for the treatment of poultry (chickens and turkeys). Baytril 10% Oral
Solution is indicated for these animals.

User safety
Wear impervious gloves when handling the product.
Wash any splashes from skin or eyes immediately with water.
Wash hands and exposed skin after use.
Do not eat, drink or smoke whilst using the product.

Withdrawal Periods
Calves must not be slaughtered for human consumption during treatment. Calves may be slaughtered for
human consumption only after 8 days from the last treatment.
Not for use in exotic animals or birds intended for human consumption.

Pharmaceutical precautions
Do not store above 25°C.
Store in a dry place.
Keep out of reach of children.
Following withdrawal of the first dose use the product within 28 days.
Discard unused material.
Any medicated liquid remaining 24 hours after preparation must be discarded.
Any unused product and containers should be disposed of in accordance with national requirements.

Further information
Enrofloxacin is a synthetic, broad spectrum antimicrobial substance, belonging to the fluoroquinoline
group of antibiotics.
Enrofloxacin is bactericidal in action with activity against Gram positive and Gram negative bacteria and
mycoplasmas. The mechanism of action of the quinolones is unique among antimicrobials - they act
primarily to inhibit bacterial DNA gyrase, an enzyme responsible for controlling the supercoiling of
bacterial DNA during replication. Resealing of the double stranded helix is inhibited resulting in
irreversible degradation of the chromosomal DNA. The fluoroquinolones also possess activity against
bacteria in the stationary phase by an alteration of the permeability of the outer membrane phospholipid
cell wall.
The pharmacokinetics of enrofloxacin are such that both oral and parenteral administration leads to
similar serum levels. Enrofloxacin possesses a high distribution volume. Tissue levels 2-3 times higher
than found in the serum, have been demonstrated in laboratory animals and target species. Organs in
which high levels can be expected are the lungs, liver, kidney, skin, bone and lymphatic system.
Enrofloxacin also distributes into the cerebrospinal fluid, the aqueous humour and the foetus in pregnant
animals.

Legal category
POM-V (previously POM)

Packaging Quantities
White high density polyethylene bottles with a polypropylene screw cap containing 100 ml.

Marketing authorisation number
Vm 00010/4078.